Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Fox Chase Cancer Center
Aileron Therapeutics, Inc.
GlaxoSmithKline
Medical University of South Carolina
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
GlaxoSmithKline
National Cancer Institute (NCI)
National Cancer Institute (NCI)